Conclusions
Patients with cirrhosis have a higher incidence of thrombosis and bleeding events than healthy individuals, and patients requiring anticoagulation therapy are at a high risk of bleeding. In the treatment of PE, NOACs were found not inferior to VKAs. In addition, according to the pooled data, NOACs caused a lower risk of bleeding than VKAs. Furthermore, NOACs are not significantly affected by food, thus it may be more suitable for patients with pulmonary embolism and fatty liver.